ALMS
Alumis Inc.
$23.66
-0.42%
2026-05-08
About Alumis Inc.
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Key Fundamentals
Forward P/E
-7.38
EPS (TTM)
$-2.86
ROE
-86.7%
Profit Margin
0.0%
Debt/Equity
12.25
Price/Book
8.30
Market Cap
$3.04B
Avg Volume (10D)
968K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$30.60
60D Low
$19.86
Avg Volume
1.4M
Latest Close
$23.66
Get breakout alerts for ALMS
Sign up for Breakout Scanner to receive daily notifications when ALMS triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Alumis Inc. (ALMS) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors ALMS daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. ALMS operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.